← Back to patent-cliff list
Rilertinib Mesylate
Tier C — Watch / tradeRilertinib Mesylate
-
Originator
2024
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：EGFR T790M, EGFR L858R, EGFR d746–750, EGFR L861Q
Indications (approved)：Non-small cell lung cancer
Regional status
US
-
EU
-
China
Approved
2024-06-11
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Rilertinib Mesylate?
Approved indications include: Non-small cell lung cancer.
When does the Rilertinib Mesylate patent expire?
No public expiry year is available for Rilertinib Mesylate yet; this page updates once verified.
How do I get a quote for Rilertinib Mesylate intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27